| Full text | |
| Author(s): |
Etchebehere, Elba C.
[1, 2]
;
Milton, Denai R.
[3]
;
Araujo, John C.
[4]
;
Swanston, Nancy M.
[1]
;
Macapinlac, Homer A.
[1]
;
Rohren, Eric M.
[1]
Total Authors: 6
|
| Affiliation: | [1] Univ Texas MD Anderson Canc Ctr, Dept Nucl Med, Houston, TX 77030 - USA
[2] Campinas State Univ Unicamp, Dept Nucl Med, BR-13083888 Campinas, SP - Brazil
[3] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 - USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 - USA
Total Affiliations: 4
|
| Document type: | Journal article |
| Source: | EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING; v. 43, n. 1, p. 8-20, JAN 2016. |
| Web of Science Citations: | 30 |
| Abstract | |
Purpose The aim of this study was to identify baseline features that predict outcome in Ra-223 therapy. Methods We retrospectively reviewed 110 patients with metastatic castration-resistant prostate cancer treated with Ra-223. End points were overall survival (OS), progression-free survival (PFS), bone event-free survival (BeFS), and bone marrow failure (BMF). The following parameters were evaluated prior to the first Ra-223 cycle: serum levels of hemoglobin (Hb), prostate-specific antigen (PSA), alkaline phosphatase (ALP), Eastern Cooperative Oncology Group (ECOG) status, pain score, use of chemotherapy, and external beam radiation therapy (EBRT). During/after Ra-223 we evaluated: the total number of radium cycles (Ra-Tot), the PSA doubling time (PSA(DT)), and the use of chemotherapy, EBRT, abiraterone, and enzalutamide. Results A significant reduction of ALP (p < 0.001) and pain score (p = 0.041) occurred throughout the (223) Ra cycles. The risk of progression was associated with declining ECOG status {[}hazard ratio (HR) = 3.79; p < 0.001] and decrease in PSA(DT) (HR = 8.22; p < 0.001). Ra-Tot, ALP, initial ECOG status, initial pain score, and use of abiraterone were associated with OS (p <= 0.008), PFS (p <= 0.003), and BeFS (p <= 0.020). Ra-Tot, ALP, initial ECOG status, and initial pain score were significantly associated with BMF (p <= 0.001) as well as Hb (p < 0.001) and EBRT (p=0.009). On multivariable analysis, only Ra-Tot and abiraterone remained significantly associated with OS (p < 0.001; p=0.033, respectively), PFS (p < 0.001; p=0.041, respectively), and BeFS (p < 0.001; p=0.019, respectively). Additionally, Ra-Tot (p=0.027) and EBRT (p=0.013) remained significantly associated with BMF. Conclusion Concomitant use of abiraterone and Ra-223 seems to have a beneficial effect, while the EBRT may increase the risk of BMF. (AU) | |
| FAPESP's process: | 14/03317-8 - Fluoride-18F PET/CT to evaluate effectiveness of treatment of metastatic prostate cancer with Ra-223 |
| Grantee: | Elba Cristina Sá de Camargo Etchebehere |
| Support Opportunities: | Scholarships abroad - Research |